Would you offer adjuvant chemotherapy for 1-3 node positive HR+, HER2 negative breast cancer with Mammaprint low risk to a young, pre-menopausal patient?

Until we have the results from the RxPONDER trial (which used Oncotype, not Mammaprint, but addresses this question more directly than MINDACT), we cannot rule out a potential benefit from adjuvant chemotherapy in node-positive patients like these, and thus, I would offer it while saying that the be...

I do not recommend chemotherapy for low biological risk ER+ breast cancer, including in 1-3+ lymph nodes.

In premenopausal women, one can make a case for chemotherapy for its indirect endocrine effect through ovarian ablation, but in this day and age, this is a crude way to achieve ovarian suppressi...